Which level of immunosuppression is harmful for occult hepatitis B virus infection?: ‘A million dollar’ answer
Sarah P. Georgiadou,
Sarah P. Georgiadou
Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Thessaly, Greece
Search for more papers by this author George N. Dalekos,
George N. Dalekos
Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Thessaly, Greece
Research Group of Investigational Medicine, Centre for Research and Technology-Thessaly (CE.RE.TE.TH), Institute of Biomedical Research and Technology, Larissa, Thessaly, Greece
Search for more papers by this author
Sarah P. Georgiadou,
Sarah P. Georgiadou
Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Thessaly, Greece
Search for more papers by this author George N. Dalekos,
George N. Dalekos
Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Thessaly, Greece
Research Group of Investigational Medicine, Centre for Research and Technology-Thessaly (CE.RE.TE.TH), Institute of Biomedical Research and Technology, Larissa, Thessaly, Greece
Search for more papers by this author
First published: 02 July 2009
No abstract is available for this article.
References
- 1
Ozaslan E.
Which level of immunosuppression is harmful for occult hepatitis B virus infection?
Liver Int (Letter)
2009, doi: DOI: 10.1111/j.1478-3231.2009.02050.x.
- 2
Georgiadou SP,
Zachou K,
Liaskos C, et al. Occult hepatitis B virus infection in patients with autoimmune liver diseases.
Liver Int
2009; 29: 434–42.
- 3
Liang R.
How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation.
Blood
2009; 113: 3147–53.
- 4
Yeo W,
Chan TC,
Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
J Clin Oncol
2009; 27: 605–11.
- 5
Dai MS,
Chao TY,
Kao WY,
Shyu RY,
Liu TM.
Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Ann Hematol
2004; 83: 769–74.
- 6
Iannitto E,
Minardi V,
Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy.
Eur J Haematol
2005; 74: 254–8.
- 7
Stefos A,
Gatselis N,
Zachou K, et al. Descriptive epidemiology of chronic hepatitis B by using data from a hepatitis registry in Central Greece.
Eur J Intern Med
2009; 20: 35–43.
- 8
Marzano A,
Angelucci E,
Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients.
Dig Liver Dis
2007; 39: 397–408.
